Bellerophon Therapeutics, Inc. (BLPH) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

7.03 k

Shareholding (Dec 2023)

FII

0.03%

Held by 2 FIIs

DII

96.08%

Held by 4 DIIs

Promoter

0.00%

How big is Bellerophon Therapeutics, Inc.?

22-Jun-2025

As of Dec 18, Bellerophon Therapeutics, Inc. has a market capitalization of 0.15 million, with net sales of 5.64 million and a net profit of -9.26 million over the last four quarters. As of Dec 22, the company reported shareholder's funds of 2.53 million and total assets of 7.93 million.

What does Bellerophon Therapeutics, Inc. do?

22-Jun-2025

Bellerophon Therapeutics, Inc. is a clinical-stage company focused on developing treatments for cardiopulmonary diseases. It has a market cap of $0.15 million and reported a net profit loss of $2 million as of September 2023.

Who are in the management team of Bellerophon Therapeutics, Inc.?

22-Jun-2025

As of March 2022, Bellerophon Therapeutics, Inc.'s management team includes Chairman Jonathan Peacock, CEO Fabian Tenenbaum, and Independent Directors Naseem Amin, Matthew Bennett, Scott Bruder, Mary Cloyd, and Andre Moura, who collectively guide the company's strategic direction and operations.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals: Major

Market cap

USD 0 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

2,319.92%

Debt Equity

-1.21

Return on Equity

-213.64%

Price to Book

0.04

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2023)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-65.71%

6 Months

-80.46%

1 Year

-63.08%

2 Years

-98.44%

3 Years

-99.62%

4 Years

-99.84%

5 Years

-99.76%

Bellerophon Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

46.03%

EBIT Growth (5y)

10.94%

EBIT to Interest (avg)

-19.59

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.21

Sales to Capital Employed (avg)

1.02

Tax Ratio

12.13%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

33.30%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.04

EV to EBIT

0.45

EV to EBITDA

0.45

EV to Capital Employed

4.34

EV to Sales

-0.77

PEG Ratio

Dividend Yield

2319.92%

ROCE (Latest)

973.50%

ROE (Latest)

-213.64%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 6 Schemes (3.89%)

Foreign Institutions

Held by 2 Foreign Institutions (0.03%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2023 is 0.00% vs -100.00% in Jun 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2023 is 62.75% vs -282.14% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.70",
          "val2": "-4.50",
          "chgp": "62.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "-0.80",
          "chgp": "37.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.90",
          "val2": "-5.10",
          "chgp": "62.75%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -11.24% vs 27.94% in Dec 2021",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.30",
          "val2": "-19.60",
          "chgp": "-13.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.80",
          "val2": "-17.80",
          "chgp": "-11.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQ

Sep'23

Jun'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.70

-4.50

62.22%

Interest

0.00

Exceptional Items

-0.50

-0.80

37.50%

Consolidate Net Profit

-1.90

-5.10

62.75%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2023 is 0.00% vs -100.00% in Jun 2023

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2023 is 62.75% vs -282.14% in Jun 2023

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'22

Dec'22

Dec'21

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-22.30

-19.60

-13.78%

Interest

0.00

Exceptional Items

0.00

0.20

-100.00%

Consolidate Net Profit

-19.80

-17.80

-11.24%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021

Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -11.24% vs 27.94% in Dec 2021

All Annual Results

Company CV

About Bellerophon Therapeutics, Inc.

Bellerophon Therapeutics, Inc.

Pharmaceuticals: Major

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. The Company's INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. INOpulse is designed to be compatible with many long-term oxygen therapy (LTOT) systems via nasal cannula delivery.

Company Coordinates

Company Details

184 Liberty Corner Rd Ste 302 , WARREN NJ : 07059-6796

Tel: 1 908 5744770

http://www.bellerophon.com/

Registrar Details

Bellerophon Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Bellerophon Therapeutics, Inc.?

Watch in Real-Time

What does Bellerophon Therapeutics, Inc. do?

Who are in the management team of Bellerophon Therapeutics, Inc.?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQ

Annual Results Snapshot (Consolidated) - Dec'22

About Bellerophon Therapeutics, Inc.

Company Coordinates